1. Volume 18, Issue 6, Pages 755-769 (June 2017)
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial 
Professor Helena M Earl, MBBS, Louise Hiller, PhD, Helen C Howard, PhD, Prof Janet A Dunn, PhD, Jennie Young, BA, Sarah J Bowden, PhD, Michelle McDermaid, Anna K Waterhouse, BSc, Gregory Wilson, FRCP, Rajiv Agrawal, FRCR, Susan O'Reilly, MD, Angela Bowman, MB ChB, Diana M Ritchie, MD, Andrew Goodman, MB ChB, Prof Tamas Hickish, MD, Karen McAdam, FRCP, Prof David Cameron, MD, Prof David Dodwell, MD, Daniel W Rea, FRCP, Prof Carlos Caldas, MD, Elena Provenzano, PhD, Jean E Abraham, PhD, Peter Canney, MD, Prof John P Crown, FRCPI, Prof M John Kennedy, FRCPI, Prof Robert Coleman, FRCP, Prof Robert C Leonard, MD, James A Carmichael, MD, Prof Andrew M Wardley, MD, Prof Christopher J Poole, FRCP 
The Lancet Oncology 
Volume 18, Issue 6, Pages (June 2017)
DOI: /S (17)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
The Lancet Oncology  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2 Disease-free survival and overall survival
(A) Disease-free survival. (B) Overall survival. HR=hazard ratio. *Adjusted for stratification variables.
The Lancet Oncology  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Figure 3
Disease-free survival, by prognostic factors (age, hormone receptor status, nodal status, and HER-2 status)
Size of box reflects size of sample within each stratum.
The Lancet Oncology  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

5. Figure 4
Disease-free survival, by prognostic factors (performance status, surgery, tumour size, grade, and lymphovascular space invasion)
Size of box reflects size of sample within each stratum. ECOG=Eastern Cooperative Oncology Group.
The Lancet Oncology  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

6. Figure 5
Disease-free survival, by prognostic factors (triple negative status and combined grade, hormone receptor, and HER-2 status)
Size of box reflects size of sample within each stratum.
The Lancet Oncology  , DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions